About Neuronetics, Inc.
https://www.neurostar.comNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
CEO
Keith J. Sullivan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.83M
Value:$5.01M
BLACKROCK, INC.
Shares:2.3M
Value:$4.08M
UBS GROUP AG
Shares:2.16M
Value:$3.83M
Summary
Showing Top 3 of 114
About Neuronetics, Inc.
https://www.neurostar.comNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $37.3M ▼ | $24.43M ▼ | $-9.04M ▲ | -24.25% ▲ | $-0.13 ▲ | $-6.43M ▲ |
| Q2-2025 | $38.11M ▲ | $25.82M ▼ | $-10.12M ▲ | -26.56% ▲ | $-0.15 ▲ | $-7.17M ▲ |
| Q1-2025 | $31.98M ▲ | $26.75M ▲ | $-12.68M ▼ | -39.64% ▲ | $-0.21 ▲ | $-9.86M ▲ |
| Q4-2024 | $22.49M ▲ | $26.36M ▲ | $-12.66M ▲ | -56.29% ▲ | $-0.33 ▲ | $-10.68M ▲ |
| Q3-2024 | $18.53M | $21.73M | $-13.34M | -72% | $-0.44 | $-11.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $34.65M ▲ | $145.47M ▲ | $114.11M ▲ | $27.36M ▲ |
| Q2-2025 | $17.64M ▼ | $134.65M ▼ | $103.14M ▲ | $27.15M ▼ |
| Q1-2025 | $21.43M ▲ | $141.99M ▲ | $102.46M ▼ | $35.45M ▲ |
| Q4-2024 | $19.66M ▼ | $140.9M ▲ | $109.1M ▲ | $27.71M ▲ |
| Q3-2024 | $21.44M | $74.12M | $64.74M | $9.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.12M ▲ | $-785K ▲ | $-114K ▲ | $17.9M ▲ | $17M ▲ | $-899K ▲ |
| Q2-2025 | $-10.12M ▲ | $-3.5M ▲ | $-252K ▼ | $1K ▼ | $-3.75M ▼ | $-3.76M ▲ |
| Q1-2025 | $-12.69M ▼ | $-16.99M ▼ | $-219K ▲ | $18.98M ▲ | $1.76M ▲ | $-17.21M ▼ |
| Q4-2024 | $-12.68M ▲ | $-8.6M ▼ | $-2.38M ▼ | $9.56M ▲ | $-1.41M ▲ | $-8.69M ▼ |
| Q3-2024 | $-13.34M | $-5.42M | $14K | $-16.37M | $-21.77M | $-5.8M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Medical Device Segment | $30.00M ▲ | $0 ▼ | $40.00M ▲ |
CEO
Keith J. Sullivan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:2.83M
Value:$5.01M
BLACKROCK, INC.
Shares:2.3M
Value:$4.08M
UBS GROUP AG
Shares:2.16M
Value:$3.83M
Summary
Showing Top 3 of 114